Day: May 14, 2021

14 May 2021 Notice of Q1 2021 IFRS Results   Acron (LSE: AKRN) will release its IFRS financial results for Q1 2021 on Monday, 17 May 2021 at 11.00 am (Moscow time).Media contacts: Sergey Dorofeev Anastasiya Gromova Tatiana Smirnova Public Relations Phone: +7 (495) 777-08-65 (ext. 5196) Investor contacts: Ilya Popov Sergey Smirnov Investor Relations Phone: +7 (495) 745-77-45 (ext. 5252)     Background Information Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It owns transportation and logistics...

Figure 1Zone of massive visual Cassiterite in BGH030 – 10.6 metres @ 4.85% SnFigure 2Mpama South Long section and Potential New High-grade PayshootFigure 3Mpama South Interpretation Section 9884840Figure 4Mpama South Interpretation Section 9884750Figure 5Mpama South Interpretation Section 9884650Figure 6High Priority Targets Following the Mpama North BlueprintGRAND BAIE, Mauritius, May 14, 2021 (GLOBE NEWSWIRE) — Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX, “Alphamin” or the “Company”), a producer of 4% of the world’s mined tin from its high-grade operation in the Democratic Republic of Congo, is pleased to provide initial assay results and an exploration update on its Mpama South Exploration Drilling programme. HIGHLIGHTSHigh-grade...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. “The first quarter of 2021 is marked by continual progress in our lead programs, TLC599 and TLC590, as well as the global commercialization of Ampholipad, for which we look forward to announcing the details when they are finalized,” commented George Yeh, President of TLC. “We are happy to announce that we have once again made the top 5% ranking in Taiwan’s corporate governance evaluation. Being the only biotech company to have achieved this honor seven years in a row, we think this is an incredible...

TORONTO, May 14, 2021 (GLOBE NEWSWIRE) — Victoria Gold Corp. (TSX-VGCX) (“Victoria” or the “Company”) is pleased to announce first quarter 2021 summary financial and operating results. The Company uses certain non-IFRS performance measures throughout this news release; please refer to the “Non-IFRS Performance Measures” section of this news release for more information. All amounts are in Canadian dollars unless otherwise indicated. This release should be read in conjunction with the Company’s Financial Statements and Management’s Discussion and Analysis (“MD&A”) for the three months ended March 31, 2021 and 2020, available on the Company’s website or on SEDAR. Mr. John McConnell, President and CEO commented, “As expected with seasonal ore placement on the heap leach pad, ore stacking and gold production grows quarter over...

FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021 Cash Runway into First Half of 2023 Company to host conference call today at 8:30am ET DUBLIN, Ireland and CHICAGO, May 14, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2021. “We continue to prepare for a U.S. Food and Drug Administration (FDA) advisory committee meeting and look forward to clarity from the FDA on timing. In the meantime, the FDA continues its review of our new drug application (NDA) for oral sulopenem for...

Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 14, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate developments. “The start of 2021 has been marked by substantial progress across our portfolio of targeted nucleic cancer drugs which included both presented and published data in support of our DNAbilize platform,” stated Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We recently announced the successful completion of the safety run-in of Stage 2 of the Phase 2 clinical study of prexigebersen...

CALGARY, Alberta, May 14, 2021 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “FLYHT”) would like to correct the number of shares previously announced on May 10, 2021 from an aggregate 248,355 common shares to an aggregate 434,555, subject to regulatory approval, to employees, officers and directors under the stock option plan approved at the Annual and Special Meeting held on May 6, 2021. These stock options are exercisable at a price of $0.57 per share. The options will vest 1/3 on each of May 6, 2022, 2023 and 2024 and will expire on May 6, 2025. A maximum of 10% of the issued and outstanding shares are reserved under the Company’s stock option plan. The options, and any common shares issued upon exercise of the stock options, are subject to a four-month resale restriction. About...

Downing Strategic Micro-Cap Investment Trust Plc  LEI Code: 213800QMYPUW4POFFX69  Net Asset Values  The Company announces the following, all of which is unaudited:  Total Assets – including current period revenue* at 13 May 2021 £45.85mNet Assets – including current period revenue* at 13 May 2021 £45.85mNumber of shares in issue (excluding treasury): 51,978,201   The Net Asset Value (NAV) per share at 13 May 2021 was:  Per Ordinary share (bid price) – including current period revenue* 88.21pPer Ordinary share (bid price) – excluding current period revenue* 86.99p   Ordinary share price  77.00pPremium/(Discount) to NAV (including current period revenue) (12.71%)   * Current period revenue covers the period 01/03/2020 to 13/05/2021 and includes undistributed revenue in...